Sarepta Therapeutics (SRPT) AI Stock Analysis

• Market Cap: $2.34B
• Dividend Yield: N/A
• Average Volume (3M): 3.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 47.15%
• EPS Growth: -311.26%
• Country: US
• Employees: 1,372
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.80
• Shares Outstanding: 104,787,186
• 10 Day Avg. Volume: 3,329,213
• 30 Day Avg. Volume: 3,491,253
• PEG Ratio: -0.34
• Price to Book (P/B): 7.57
• Price to Sales (P/S): 6.08
• P/FCF Ratio: -33.73
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 1.05
• Enterprise Value/Gross Profit: 1.38
• Enterprise Value/Ebitda: -14.04
• 1Y Price Target: $21.69
• Price Target Upside: -1.94% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 19
• EPS Forecast (FY): -4.99
• Revenue Forecast (FY): $2.12B

• Rating: 51 Neutral
• Price Target: $21.00 ▼(-5.06% Downside)

Sarepta Therapeutics' overall stock score reflects significant financial challenges, particularly in profitability and cash flow, despite some positive technical indicators and strategic debt management. The company's valuation remains a concern due to negative earnings, and while recent earnings call and corporate events provide some optimism, they are not enough to offset the financial weaknesses.

Positive Factors

Revenue Growth

Sarepta's strong revenue growth rate of 47.15% indicates robust demand for its products, suggesting a solid market position and potential for sustained financial performance.

Regulatory Approval

FDA approval for dosing in Cohort 8 of ENDEAVOR enhances Sarepta's product pipeline, potentially leading to new treatment options and revenue streams.

Debt Management

By extending debt maturities, Sarepta improves its financial stability and liquidity, providing more flexibility for long-term strategic investments.

Negative Factors

Profitability Challenges

Ongoing profitability issues, as indicated by negative margins, could limit Sarepta's ability to reinvest in growth and maintain competitive positioning.

Cash Flow Issues

Persistent negative cash flows highlight operational inefficiencies, potentially constraining Sarepta's capacity to fund R&D and other strategic initiatives.

Regulatory Risks

The FDA's addition of a Boxed Warning for Elevidys could affect its market acceptance and sales, posing a risk to Sarepta's revenue from this key product.

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Sarepta Therapeutics generates revenue primarily through the commercialization of its approved therapies, such as Eteplirsen, which provides a direct sales revenue stream. Additionally, the company engages in partnerships and collaborations with other pharmaceutical companies and research institutions to develop and commercialize its drug candidates. These partnerships often involve upfront payments, milestone payments as products advance through clinical trials, and royalties on future sales. Furthermore, Sarepta may receive funding from grants and research initiatives aimed at advancing its therapeutic pipeline, which contributes to its overall revenue model.

Sarepta Therapeutics Financial Statement Overview

Summary

Sarepta Therapeutics faces significant financial challenges, particularly in achieving consistent profitability and positive cash flows. Despite improvements in leverage and asset management, the company struggles with revenue growth and profitability.

Income Statement

Sarepta Therapeutics has shown inconsistent revenue growth, with a recent decline in TTM. The company has struggled with profitability, as indicated by negative net profit margins and EBIT margins over the years. Despite a strong gross profit margin, the overall income statement reflects challenges in achieving sustainable profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, which has improved over time, indicating better leverage management. However, the return on equity remains negative, highlighting ongoing profitability challenges. The equity ratio is stable, suggesting a balanced asset structure.

Cash Flow

Sarepta's cash flow statement reveals negative operating and free cash flows, with a declining trend in free cash flow growth. The company has a high free cash flow to net income ratio, indicating cash flow challenges despite net income improvements in some periods.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.41B	1.90B	1.24B	933.01M	701.89M	540.10M
Gross Profit	1.84B	1.58B	1.09B	793.02M	604.84M	476.72M
EBITDA	-180.69M	316.89M	-453.69M	-594.85M	-317.41M	-453.38M
Net Income	-271.51M	235.24M	-535.98M	-703.49M	-418.78M	-554.13M
Balance Sheet
Total Assets	3.49B	3.96B	3.26B	3.13B	3.15B	2.98B
Cash, Cash Equivalents and Short-Term Investments	850.99M	1.35B	1.68B	1.99B	2.12B	1.94B
Total Debt	1.25B	1.34B	1.40B	1.62B	1.15B	1.09B
Total Liabilities	2.17B	2.44B	2.41B	2.74B	2.22B	2.22B
Stockholders Equity	1.32B	1.53B	859.34M	384.95M	928.01M	761.76M
Cash Flow
Free Cash Flow	-343.58M	-342.74M	-588.34M	-357.60M	-481.66M	25.26M
Operating Cash Flow	-230.05M	-205.79M	-500.99M	-325.35M	-443.17M	107.47M
Investing Cash Flow	505.15M	755.56M	-165.80M	-1.05B	495.41M	-121.72M
Financing Cash Flow	37.65M	124.81M	125.00M	232.51M	561.57M	682.32M

Sarepta Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Positive. The current price of 22.12 is above the 20-day moving average (MA) of 21.60, above the 50-day MA of 20.78, and below the 200-day MA of 30.48, indicating a neutral trend. The MACD of 0.45 indicates Negative momentum. The RSI at 56.10 is Neutral, neither overbought nor oversold. The STOCH value of 70.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRPT.

Sarepta Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.61B	-81.72	-28.17%	―	129.21%	80.35%
BCRX	55 Neutral	$1.62B	-161.31	―	―	45.38%	92.85%
MESO	53 Neutral	$2.50B	-23.06	-18.96%	―	191.53%	5.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRPT	51 Neutral	$2.34B	-7.65	-21.37%	―	47.15%	-311.26%
DYN	43 Neutral	$3.29B	-5.48	-60.66%	―	―	-2.75%
COGT	37 Underperform	$6.04B	-16.40	-95.40%	―	―	4.32%

Sarepta Therapeutics Corporate Events

Sarepta Therapeutics Extends Debt Maturities with New Notes

On December 10, 2025, Sarepta Therapeutics, Inc. entered into privately negotiated exchange agreements with certain holders of its 1.25% Convertible Senior Notes due 2027, including an entity affiliated with board member Michael Chambers, to exchange approximately $291.4 million in principal of the existing notes for an equal principal amount of new 4.875% Convertible Senior Notes due 2030 plus about $31.6 million in cash. The new notes were issued on December 18, 2025, under an existing indenture and form part of the same series as the $602.0 million of 4.875% Convertible Senior Notes due 2030 issued in August 2025, bringing the total outstanding principal of that 2030 series to approximately $893.4 million and effectively extending the company’s debt maturity profile while modestly increasing its cash outlay to participating noteholders.

Sarepta Therapeutics Refinances Convertible Senior Notes

On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to refinance approximately $291.4 million of its 1.25% Convertible Senior Notes due 2027. These notes will be exchanged for new 4.875% Convertible Senior Notes due 2030 and approximately $31.6 million in cash. The exchange aims to enhance the company’s financial structure by consolidating its debt under a new series of notes, increasing the total principal amount of the 2030 notes to $893.4 million. This move could influence the market price of Sarepta’s common stock and notes, as the placement agent plans to purchase shares in privately negotiated transactions.

Sarepta Grants CEO Equity Awards After Eight Years

On December 7, 2025, Sarepta Therapeutics‘ Board of Directors granted equity awards to CEO Douglas S. Ingram under the company’s 2018 Equity Incentive Plan. This marks the first equity grant for Mr. Ingram since 2017, with the award divided equally between time-based restricted stock units and performance-based awards, each valued at approximately $6 million. The performance-based portion is contingent on the company’s Incentive EBITDA performance over a two-year period, potentially doubling in value if targets are met, and is subject to Mr. Ingram’s continued service.